Vascular Biogenics Ltd. - Ordinary Shares (VBLT) News
Filter VBLT News Items
VBLT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VBLT News Highlights
- For VBLT, its 30 day story count is now at 3.
- Over the past 13 days, the trend for VBLT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TEL and MA are the most mentioned tickers in articles about VBLT.
Latest VBLT News From Around the Web
Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the Compensation Committee of VBL’s Board of Directors approved the grant effective February 13, 2022 of a non-qualified stock option to purchase an aggregate of 300,000 ordinary shares of VBL as an inducement ma |
Vascular Biogenics (VBLT) Investor Presentation - SlideshowNo summary available. |
VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor ConferenceTEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will participate in a fireside chat at the Guggenheim Oncology Conference being held virtually on February 9 – 11, 2022. Management will also attend |
VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial OfficerCCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian cancer, expected to be completed this quarter; PFS co-primary endpoint readout expected in 2H22 has potential to support BLA filing TEL AVIV, Israel and NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class ther |
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual ConferenceTEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview at the H.C. Wainwright BioConnect Virtual Conference being held on January 10 – 13, 2022. H.C. Wainwright BioConnect Virtu |
BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate FailureBridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues. |
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator ProgramVBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL AVIV, Israel and NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it has been selected for € |
Reata (RETA) Falls on Negative Advisory Committee OutcomeAn FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome. |
Vascular Biogenics (NASDAQ:VBLT) Stock Price Crosses Below 50 Day Moving Average of $2.24Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.24 and traded as low as $2.05. Vascular Biogenics shares last traded at $2.06, with a volume of 296,919 shares traded. Several research analysts recently commented on the company. HC [] |
Reata (RETA) Plunges on FDA Concerns for Kidney Failure DrugThe FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow. |